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Background: We assessed the safety and immunogenicity of the RTS,S/AS01 malaria vaccine in a subset of
children identified as HIV-infected during a large phase III randomized controlled trial conducted in
seven sub-Saharan African countries.
Methods: Infants 6–12 weeks and children 5–17 months old were randomized to receive 4 RTS,S/AS01
doses (R3R group), 3 RTS,S/AS01 doses plus 1 comparator vaccine dose (R3C group), or 4 comparator vac-
cine doses (C3C group) at study months 0, 1, 2 and 20. Infants and children with WHO stage III/IV HIV
disease were excluded but HIV testing was not routinely performed on all participants; our analyses
included children identified as HIV-infected based on medical history or clinical suspicion and confirmed
by polymerase chain reaction or antibody testing. Serious adverse events (SAEs) and anti-
circumsporozoite (CS) antibodies were assessed.
Results: Of 15459 children enrolled in the trial, at least 1953 were tested for HIV and 153 were confirmed
as HIV-infected (R3R: 51; R3C: 54; C3C: 48). Among these children, SAEs were reported for 92.2% (95% CI:
81.1–97.8) in the R3R, 85.2% (72.9–93.4) in the R3C and 87.5% (74.8–95.3) in the C3C group over a median
follow-up of 39.3, 39.4 and 38.3 months, respectively. Fifteen HIV-infected participants in each group
(R3R: 29.4%, R3C: 27.8%, C3C: 31.3%) died during the study. No deaths were considered vaccination-
related. In a matched case-control analysis, 1 month post dose 3 anti-CS geometric mean antibody con-
centrations were 193.3 EU/mL in RTS,S/AS01-vaccinated HIV-infected children and 491.5 EU/mL in RTS,S/
AS01-vaccinated immunogenicity controls with unknown or negative HIV status (p = 0.0001).
Conclusions: The safety profile of RTS,S/AS01 in HIV-infected children was comparable to that of the com-
parator (meningococcal or rabies) vaccines. RTS,S/AS01 was immunogenic in HIV-infected children but
antibody concentrations were lower than in children with an unknown or negative HIV status.
Clinical trial registration: ClinicalTrials.gov: NCT00866619.
 2019 GlaxoSmithKline Biologicals S.A. Published by Elsevier Ltd. This is an open access article under the
CC BY license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
Malaria and human immunodeficiency virus (HIV) infection
remain among the most important public health challenges of
our times. An estimated 219 million malaria cases and 435,000
malaria-related deaths occurred worldwide in 2017, with sub-
Saharan Africa carrying more than 90% of the global malaria bur-
den [1]. Of all malaria-related deaths worldwide, 61% were in chil-
dren under 5 years old [1]. In 2017, of the estimated 36.9 million
people living with HIV and 940,000 HIV-related deaths globally,
approximately 70% were in sub-Saharan Africa [2]. Children
younger than 15 years account for approximately 5% of all people
living with HIV and 12% of all HIV-related deaths [2]. Most of these
children are infected with HIV in utero, during birth or through
breastfeeding.
Given their geographic overlap, malaria and HIV co-infection is
common in sub-Saharan Africa [3,4]. It is therefore important to
evaluate the safety and immunogenicity of any malaria candidate
vaccine intended for use in this region in HIV-infected children.
The pre-erythrocytic RTS,S/AS01 vaccine (GSK) contains portions
of the Plasmodium falciparum circumsporozoite (CS) protein and
has been shown to be effective in reducing the malaria burden in
children when used alongside other malaria interventions in phase
II and III clinical trials [5–10]. The safety profile of the vaccine is in
line with that of other pediatric vaccines [5–10] and RTS,S/AS01
received a positive scientific opinion from the European Medicines
Agency in 2015 [11]. The World Health Organization (WHO) rec-
ommended pilot implementation of the vaccine in children 5–
17 months of age in sub-Saharan Africa to answer outstanding
questions on feasibility of reaching children with the 4 doses
needed for optimal benefit, monitor the safety profile of RTS,S/
AS01 in real-life settings, and measure impact [12].
One prior randomized controlled phase III trial specifically
assessed the safety and immunogenicity of a 3-dose RTS,S/AS01
vaccination series in Kenyan children with WHO stage I or II HIVdisease, most of whom received antiretroviral therapy (ART) to
delay disease progression and cotrimoxazole prophylaxis to pre-
vent opportunistic infections. This prior trial showed that RTS,S/
AS01 was well tolerated and immunogenic in HIV-infected chil-
dren on ART [13].
Here, we report results of RTS,S/AS01 vaccination in a small
subset of children identified as HIV-infected during a separate
large phase III randomized controlled efficacy trial which enrolled
more than 15,000 children in seven countries in sub-Saharan
Africa. The efficacy, safety and immunogenicity findings for the
overall population enrolled in this trial, comparing a 3- or 4-dose
RTS,S/AS01 schedule with 4 doses of comparator vaccines, were
published [7–10]. Although HIV testing was not routinely per-
formed, a small proportion of participants were identified as
HIV-infected during the trial based on their medical condition,
with HIV diagnoses made in the context of the routine clinical care
provided at the study centers (and confirmation by polymerase
chain reaction [PCR] or antibody testing). This subset therefore
provided another opportunity to evaluate safety and immuno-
genicity of RTS,S/AS01 in HIV-infected children.2. Methods
2.1. Study design, participants and vaccines
The initial large phase III double-blind (observer-blind) ran-
domized controlled efficacy trial was performed between 27March
2009 and 31 January 2014 at eleven centers in seven countries in
sub-Saharan Africa: Burkina Faso, Gabon, Ghana, Kenya, Malawi,
Mozambique and Tanzania. The study centers represented differ-
ent geographic areas with diverse malaria transmission intensities
[9,14] and overlapping background HIV prevalence [2]. Details on
the study centers and methods have been described previously
[7–10,15–18]. Insecticide-treated bednets were made available to
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(approximately 85% in participants enrolled at 6–12 weeks of age
and 75% in participants enrolled at 5–17 months of age) but varied
between study centers [10].
The study was registered on ClinicalTrials.gov (NCT00866619)
and was conducted in accordance with the Declaration of Helsinki,
International Conference on Harmonization Good Clinical Practice
guidelines and local rules and regulations. The protocol and other
study-related documents were approved by the ethical review
board at each study center and partner institutions and by the
national regulatory authority in each country. A summary of the
protocol is available at https://www.gsk-studyregister.com/study/
3251. Anonymized individual participant data and study docu-
ments can be requested for further research from www.clinical-
studydatarequest.com. All participants’ parents or legally
authorized representatives (LARs) provided signed or thumb-
printed and witnessed informed consent prior to enrollment. An
independent data monitoring committee oversaw the safety of
the participants by regular review of unblinded study data [10].
In the initial trial, we enrolled infants 6–12 weeks of age and
children 5–17 months of age (irrespective of their HIV status)
and randomized them 1:1:1 to receive either 4 doses of RTS,S/
AS01 vaccine (R3R group), 3 doses of RTS,S/AS01 vaccine followed
by a dose of comparator vaccine (R3C group), or 4 doses of com-
parator vaccine (C3C group). Vaccines in the three groups were
given intramuscularly in the thigh or deltoid (depending on the
participant’s age) at study months 0, 1, 2 and 20. RTS,S/AS01 con-
tains portions of the P. falciparum CS protein, fused to hepatitis B
surface antigen (HBsAg), together with free HBsAg and is adju-
vanted with the adjuvant system (AS) AS01 [19]. For the first 3
doses, we used a meningococcal C CRM197 conjugate vaccine
(MenC-CRM, Menjugate, Novartis) as comparator in infants
enrolled at 6–12 weeks of age and a rabies vaccine (Verorab, Sanofi
Pasteur) in children enrolled at 5–17 months of age. For the fourth
dose, we used MenC-CRM as comparator in both age categories.
Infants in the 6–12 weeks age category received other routine
pediatric vaccines according to local Expanded Program on Immu-
nization policy [10].
The children and their parents/LARs as well as those responsible
for the evaluation of study endpoints were unaware of which vac-
cine was given. The study staff responsible for preparation and
administration of vaccines (and thus aware of vaccine assignment)
were not involved in any of the analyses.
Detailed inclusion and exclusion criteria for enrollment in the
initial study have been described previously [10]. Children with
active WHO stage III or IV HIV disease [20] at screening were
excluded from the initial study. The current analyses included chil-
dren identified as HIV-infected, based on their general medical his-
tory taken at screening or based on clinical suspicion during the
course of the trial, and confirmed to be HIV positive by PCR or—
for children 18 months or older—by antibody testing. Importantly,
HIV testing was not a trial procedure and was thus not routinely
performed on all participants. HIV-testing practices differed
between centers, depending on national guidelines and local prac-
tices. Consequently, some HIV-infected children might not have
been identified as such. Voluntary counseling and testing, highly
active ART and prevention of mother-to-child transmission were
available at the study centers or in health facilities within the
study area. The centers followed the national recommendations
for the treatment and management of HIV-infected children. Data
on ART use were not systematically collected during the study.
We also performed a matched case-control analysis to compare
RTS,S/AS01 immunogenicity in children confirmed as HIV-infected
with that in controls not identified as HIV-infected. This immuno-
genicity control cohort included children with unknown HIV status
(not tested) and children tested and found to be HIV-negative.2.2. Safety outcomes and assessments
We assessed the occurrence of serious adverse events (SAEs) in
HIV-infected children, within one month following each vaccine
dose and over the entire follow-up period. In the protocol, these
analyses were planned by age category, but because of the limited
number of confirmed HIV-infected children, they were also per-
formed pooled across age categories. SAEs were defined as any
untoward medical occurrence that resulted in death, was life-
threatening, required hospitalization or prolongation of existing
hospitalization or resulted in disability/incapacity. SAEs were col-
lected by passive surveillance at the health facilities and through
monthly home visits. Seizures occurring within 30 days of vaccina-
tion were also collected as SAEs; those occurring within 7 days
post-vaccination were further analyzed according to the Brighton
collaboration guidelines [21]. Potential immune-mediated disor-
ders (pIMDs) occurring throughout the study were collected as
SAEs according to a predefined list provided in the study protocol
[22]. HIV infection could be reported as an SAE during the course
of the study based on the investigators’ judgment of whether it
met the criteria of an SAE. To enable accurate SAE reporting, inves-
tigators were encouraged to perform HIV testing if HIV infection
was suspected. We also assessed the occurrence of fatal SAEs in
boys and girls separately (post hoc analysis).
The investigators assessed the relationship between the
reported SAEs and vaccination based on their clinical judgement.
Verbal autopsies were performed on deaths that occurred outside
the health facilities according to WHO guidelines [23]. The cause
of death was determined by a panel of three experienced verbal
autopsy reviewers, as detailed previously [22].
2.3. Immunogenicity outcomes and assessments
We assessed anti-CS antibody concentrations on blood samples
collected at screening and 1 month post-dose 3 in HIV-infected
children. Analyses in the HIV-infected population were done for
each age category (as planned per protocol) and pooled across
age categories. The analyses of anti-CS antibody responses at later
time points (18 and 30 months post-dose 3), planned per protocol,
were canceled because HIV-infected participants who survived
until these later time points may differ from those who did not
(e.g., by having less severe HIV illness or by accessing ART) and
including them could potentially introduce bias related to the
anti-CS antibody response. The analyses of anti-HBs antibody
responses were also canceled because anti-HBs results had mean-
while been published for the prior study that was specifically
designed to assess RTS,S/AS01 immunogenicity in HIV-infected
children [13]. Anti-CS antibodies were measured at the Center for
Vaccinology (Ghent University, Belgium) using an enzyme-linked
immunosorbent assay (ELISA) based on the binding of serum anti-
bodies to the recombinant R32LR protein, as described previously
[24]. The assay cut-off was 0.5 ELISA units (EU)/mL.
2.4. Statistical analyses
No formal sample size calculations were performed for the
analyses on the HIV-infected subset since this subset was defined
by the total population enrolled in the initial trial [7–9] and the
number of participants confirmed as HIV-infected. Statistical anal-
yses of the endpoints presented here were descriptive and were
performed using SAS Drug Development.
We performed all safety assessments on the intent-to-treat
(ITT) population of HIV-infected participants, which included all
HIV-infected children confirmed throughout the study (as
described above) who had received at least 1 dose of RTS,S/AS01
or comparator vaccine. Safety assessments pertaining to the 30-
900 L. Otieno et al. / Vaccine 38 (2020) 897–906day period after the fourth dose were performed on HIV-infected
participants who had received a fourth dose. We calculated the
proportions of participants reporting SAEs, classified by Medical
Dictionary for Regulatory Activities preferred term, with exact
95% confidence intervals (CIs) for the various follow-up periods.
We generated survival curves based on all follow-up data from
dose 1 to study end for the individual and pooled age categories.
A log-rank test was performed on the three groups.
We performed the primary immunogenicity assessments on the
per protocol population which included all participants confirmed
HIV-infected by 2 May 2012 (data lock point when most children
had performed their study month 20 visit), who were primed with
3 doses of RTS,S/AS01 or comparator vaccine per protocol and com-
plied with all protocol-defined procedures. We calculated the per-
centages of participants who were seropositive for anti-CS
antibodies (i.e., with concentrations 0.5 EU/mL) and anti-CS anti-
body geometric mean concentrations (GMCs) with 95% CIs.
The matched case-control analysis was performed on the total
vaccinated population of HIV-infected cases and immunogenicity
controls. Each participant confirmed as HIV-infected by the data
lock point, primed with 3 doses of RTS,S/AS01 and with an anti-
CS serology result available at 1 month post-dose 3 (case), was
matched (1:1) with another RTS,S/AS01-vaccinated child not iden-
tified as HIV-infected by the data lock point (immunogenicity con-
trol with HIV-negative or unknown HIV status). The matching
algorithm identified all children who had received the first 3 doses
of RTS,S/AS01, who were not confirmed as HIV-infected, had an
anti-CS result available for the 1 month post-dose 3 timepoint,
were in the same treatment group as the HIV-infected child, had
identical values on all considered matching variables (center, sex,
age category, ethnic group, and the number of hepatitis B vaccine
doses received prior to RTS,S/AS01 dose 1), and were not yet
selected as immunogenicity control for another HIV-infected child.
If several participants were eligible as immunogenicity controls for
a certain HIV-infected child, the control was randomly selected
from these participants. To assess if the anti-CS response differed
between HIV-infected participants and immunogenicity controls,
we compared the log-transformed mean anti-CS concentrations
between both groups using a paired t-test.3. Results
3.1. Study population
15,459 participants were enrolled in the initial large phase III
trial (8922 in the 5–17 months and 6537 in the 6–12 weeks age
category), 1953 were reported to have been tested for HIV at least
once and 153 were confirmed as HIV-infected during the study:
51/5156 (1.0%) in the R3R group, 54/5150 (1.0%) in the R3C group
and 48/5153 (0.9%) in the C3C group (Fig. 1 and Supplementary
Table 1). Of these, 96 received the fourth vaccine dose and 87 com-
pleted the study (Fig. 1).
In the RTS,S/AS01-vaccinated groups, HIV-infected participants
were approximately equally distributed between the 6–12 weeks
and 5–17 months age categories, while in the C3C group, two
thirds of HIV-infected participants were in the older age category
(Table 1). Supplementary Fig. 1 provides the age distribution at
positive HIV test and does not indicate a major difference between
groups. Apart from a trend for a higher proportion of girls in the
R3C group, most baseline characteristics in the ITT population were
similar between groups (Table 1). The highest number of HIV-
infected participants were reported in Siaya, Kenya (56; 37%), Man-
hiça, Mozambique (37; 24%), Kombewa, Kenya (19; 12%) and
Lilongwe, Malawi (18; 12%) (Table 1). This corresponded to 3.5%
of all participants enrolled in Siaya, 2.3% of those enrolled in Man-hiça, 1.2% in Kombewa and 1.1% in Lilongwe (Supplementary
Table 2). HIV testing rates varied substantially across centers and
were highest in Siaya (55.5% of those enrolled at this center), Kom-
bewa (19.6%), Lilongwe (16.8%) and Kilifi (15.6%) and lowest in
Nanoro (0.08%) (Supplementary Table 2).
The per protocol population for immunogenicity comprised 56
RTS,S/AS01-vaccinated and 23 comparator-vaccinated participants
identified as HIV-infected. Baseline characteristics of the per proto-
col population for immunogenicity were in line with those of the
total ITT population of HIV-infected participants (Supplementary
Table 3).
3.2. Safety
The median follow-up time between dose 1 and study end in
the ITT population of HIV-infected participants was 39.3 months
in the R3R group, 39.4 months in the R3C group and 38.3 months
in the C3C group. During this period, SAEs were reported for
92.2% (95% CI: 81.1–97.8) of HIV-infected participants in the R3R
group, 85.2% (72.9–93.4) in the R3C group and 87.5% (74.8–95.3)
in the C3C group across the two age categories, with comparable
rates in both age categories (Table 2). These percentages were sim-
ilar when excluding SAEs with a Medical Dictionary for Regulatory
Activities code referring to HIV infection (Table 2), indicating that
most children experienced other SAEs in addition to HIV infection.
The most commonly reported SAEs (aside from HIV infection) were
pneumonia, gastroenteritis, different forms of malnutrition, malar-
ia, and anemia, each reported at similar frequencies across groups
(Supplementary Tables 4–6). Meningitis—which was identified as a
safety signal after RTS,S/AS01 vaccination in the 5–17 months age
category in the total population of the initial study [7,9,10,25]—
was diagnosed for two (3.9%) HIV-infected participants in the
R3R group, both in the 5–17 months age category, one (1.9%) in
the R3C group in the 6–12 weeks age category, and one (2.1%) in
the C3C group in the 5–17 months age category (Supplementary
Tables 4–6). The etiology was identified for the case in the R3C
group (pneumococcal meningitis).
Two SAEs were judged as related to vaccination. Both were
cases of febrile convulsion in one participant in the R3R group in
the 5–17 months age category; the first one occurred 2 days after
administration of dose 3, the second one on the day of dose 4
administration.
Fifteen HIV-infected participants in each group (R3R: 29.4%,
R3C: 27.8%, C3C: 31.3%) died during the study (Table 2). No deaths
were deemed related to vaccination. The most frequently reported
fatal SAEs (aside from HIV infection) were lower respiratory tract
infections and gastroenteritis (Supplementary Table 7). No statisti-
cally significant differences in survival duration were observed
between RTS,S/AS01-vaccinated and comparator-vaccinated HIV-
infected children (log-rank p values equaled 0.9051 for the overall
population, 0.4025 for the 5–17 months and 0.7665 for the 6–
12 weeks age category) (Fig. 2 and Supplementary Fig. 2).
In the overall population of the initial large phase III study, a
post hoc analysis showed that all-cause mortality in RTS,S/AS01-
vaccinated girls was ~1.8-fold higher than that in comparator-
vaccinated girls, an imbalance not observed in boys [22,26]. A
higher number (~1.9-fold) of deaths was also seen in RTS,S/AS01-
vaccinated girls compared with comparator-vaccinated girls (and
the opposite for boys) in the subset of HIV-infected children, but
95% CIs overlapped: 18/53 (34.0%; 95% CI: 21.5–48.3) RTS,S/
AS01-vaccinated girls (R3R + R3C) and 4/22 (18.2%; 5.2–40.3)
comparator-vaccinated girls (C3C) died compared to 12/52
(23.1%; 12.5–36.8) RTS,S/AS01-vaccinated boys and 11/26 (42.3%;
23.4–63.1) comparator-vaccinated boys.
Three pIMDs were reported throughout the trial among HIV-
infected children, none of which were considered related to vacci-
Fig. 1. Flow diagram. R3R, group receiving 4 doses of RTS,S/AS01; R3C, group receiving 3 doses of RTS,S/AS01 plus 1 dose of comparator vaccine; C3C, group receiving 4 doses
of comparator vaccine; ITT, intent-to-treat. aNot all HIV tests were recorded in the database for all centers; 1953 is therefore the minimum number of children tested for HIV
at least once during the study.
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each had encephalitis with a fatal outcome (onset 1 day post-dose
1 and 353 days post-dose 3, respectively) and one participant in
the C3C group had Stevens-Johnson syndrome (onset 616 days
post-dose 4) but the child recovered.
Thirty (28.6%) RTS,S/AS01-vaccinated (R3R + R3C) and 12
(25.0%) comparator-vaccinated HIV-infected participants experi-
enced an SAE within 30 days after any of the first 3 vaccine doses.
Most were HIV and opportunistic infections, with no apparent
imbalances between groups (Table 2 and Supplementary Table 8).
Four (12.1%) HIV-infected participants in the R3R group, three
(8.6%) in the R3C group and one (3.6%) in the C3C group experi-
enced an SAE within 30 days after the fourth dose (Table 2 and
Supplementary Table 9).3.3. Immunogenicity
One month post-dose 3, all HIV-infected RTS,S/AS01 recipients
in the per protocol population for immunogenicity were seroposi-
tive for anti-CS antibodies in both age categories, compared to
23.5% (5–17 months) and 0.0% (6–12 weeks) in the C3C group
(Table 3). While anti-CS antibody GMCs at screening were similarly
low between groups (0.3 EU/mL), they were substantially higher in
RTS,S/AS01-vaccinated than in comparator-vaccinated HIV-infected children 1 month post-dose 3 (188.7 vs 0.5 EU/mL;
Table 3).
Results from the matched case-control analysis on the total vac-
cinated population of HIV-infected cases and immunogenicity con-
trols indicated that anti-CS antibody GMCs after 3 doses of RTS,S/
AS01 were lower in vaccinated HIV-infected participants than in
vaccinated immunogenicity controls who were HIV-negative or
had an unknown HIV status (193.3 versus 491.5 EU/mL,
p = 0.0001, Table 4).
A ‘‘Plain Language Summary” section (Fig. 3) summarizes these
findings and highlights their clinical relevance.
4. Discussion
Previous findings from our large phase III efficacy trial con-
ducted across different malaria transmission settings in sub-
Saharan Africa demonstrated that the RTS,S/AS01 vaccine can
reduce clinical and severe malaria rates when administered as a
3- or 4-dose regimen in children [7–10]. The rates of SAEs reported
in the overall population in this trial were similar in the RTS,S/
AS01-vaccinated and MenC-CRM- or rabies-vaccinated comparator
groups [7–10,22]. In the current analyses, we have shown that for
the subset of HIV-infected children in this trial (approximately 1%
of the overall study population), the incidence of SAEs was also
similar between vaccine groups, both when assessed over the
Table 1
Baseline characteristics of the ITT population of HIV-infected participants.
Characteristic R3R group
N = 51
R3C group
N = 54
C3C group
N = 48
Age category
5–17 months, n (%) 24 (47.1) 29 (53.7) 32 (66.7)
6–12 weeks, n (%) 27 (52.9) 25 (46.3) 16 (33.3)
Mean age at dose 1 ± SD
5–17 months, months 10.3 ± 3.4 9.7 ± 4.0 10.8 ± 3.8
6–12 weeks, weeks 7.6 ± 1.5 7.6 ± 1.6 7.5 ± 1.5
Mean age at HIV positive test ± SD
5–17 months, months 17.9 ± 7.5 22.4 ± 13.1 17.7 ± 12.3
6–12 weeks, months 9.1 ± 7.8 10.0 ± 8.8 15.6 ± 9.9
Both age categories, months 13.8 ± 8.8 17.1 ± 12.8 17.5 ± 11.6
Female sex, n (%) 19 (37.3) 34 (63.0) 22 (45.8)
Mean height-for-age z-score ± SD 1.6 ± 1.1 1.7 ± 1.5a 1.6 ± 1.3
Mean weight-for-age z-score ± SD 1.1 ± 1.2b 1.4 ± 1.4 1.1 ± 1.1
Mean Hb ± SD, g/dL 10.2 ± 1.7 10.3 ± 1.6 10.2 ± 1.7
Moderate anemiac, n (%) 4 (7.8) 3 (5.6) 2 (4.2)
Study center, n (%)
Agogo, Ghana 2 (3.9) 0 (0.0) 1 (2.1)
Bagamoyo, Tanzania 2 (3.9) 1 (1.9) 1 (2.1)
Kilifi, Kenya 0 (0.0) 2 (3.7) 2 (4.2)
Kintampo, Ghana 0 (0.0) 5 (9.3) 3 (6.3)
Kombewa, Kenya 8 (15.7) 5 (9.3) 6 (12.5)
Korogwe, Tanzania 1 (2.0) 2 (3.7) 0 (0.0)
Lambaréné, Gabon 0 (0.0) 0 (0.0) 1 (2.1)
Lilongwe, Malawi 3 (5.9) 9 (16.7) 6 (12.5)
Manhiça, Mozambique 11 (21.6) 12 (22.2) 14 (29.2)
Nanoro, Burkina Faso 0 (0.0) 0 (0.0) 0 (0.0)
Siaya, Kenya 24 (47.1) 18 (33.3) 14 (29.2)
ITT, intent-to-treat; R3R, group receiving 4 doses of RTS,S/AS01; R3C, group
receiving 3 doses of RTS,S/AS01 plus 1 dose of comparator vaccine; C3C, group
receiving 4 doses of comparator vaccine; N, number of participants in the ITT
population of HIV-infected participants; n (%), number (percentage) of participants
in a given category; SD, standard deviation; Hb, hemoglobin.
a Height-for-age z-score available for 52 participants in the R3C group.
b Weight-for-age z-score available for 50 participants in the R3R group.
c Hb < 8 g/dL.
Table 2
Number and percentage of HIV-infected participants for whom serious adverse events wer
HIV-infected participants).
R3R R3C
N n (%, 95% CI) N
At least one SAE between dose 1 and study end
Total 51 47 (92.2, 81.1–97.8) 54
5–17 months 24 22 (91.7, 73.0–99.0) 29
6–12 weeks 27 25 (92.6, 75.7–99.1) 25
At least one SAE (excluding HIV infectiona) between dose 1 and study end
Total 51 43 (84.3, 71.4–93.0) 54
5–17 months 24 21 (87.5, 67.6–97.3 29
6–12 weeks 27 22 (81.5, 61.9–93.7) 25
Fatalities between dose 1 and study end
Total 51 15 (29.4, 17.5–43.8) 54
5–17 months 24 6 (25.0, 9.8–46.7) 29
6–12 weeks 27 9 (33.3, 16.5–54.0) 25
At least one SAE within 30 days after any of the first 3 doses
Total 51 14 (27.5, 15.9–41.7) 54
5–17 months 24 7 (29.2, 12.6–51.1) 29
6–12 weeks 27 7 (25.9, 11.1–46.3) 25
At least one SAE within 30 days after dose 4
Total 33 4 (12.1, 3.4–28.2) 35
5–17 months 17 2 (11.8, 1.5–36.4) 22
6–12 weeks 16 2 (12.5, 1.6–38.3) 13
ITT, intent-to-treat; R3R, group receiving 4 doses of RTS,S/AS01; R3C, group receiving 3 do
comparator vaccine; N, number of participants with at least one administered vaccine
participants who received dose 4; n (%), number (percentage) of participants reporting
a Excluding SAEs with Medical Dictionary for Regulatory Activities codes referring to
WHO clinical stage III” and ‘‘HIV infection WHO clinical stage IV”.
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icant differences in mortality were observed between groups
although samples sizes were small. RTS,S/AS01 was immunogenic
in HIV-infected participants, but antibody concentrations were
lower than in matched immunogenicity controls with an unknown
or negative HIV status.
A prior study designed to evaluate the RTS,S/AS01 vaccine in
HIV-infected children also showed similar rates of SAEs in RTS,S/
AS01 and rabies comparator vaccine recipients [13]. This agrees
with other non-replicating vaccines that are not generally associ-
ated with an increased risk of complications when administered
to HIV-infected children, in contrast to some live-attenuated vacci-
nes [27–30].
Our results allow a direct comparison of the safety outcomes in
HIV-infected children with those in the overall study population
(HIV-infected and uninfected) in the same settings. While no
imbalance in the SAE incidence was found between vaccine groups
in either of these populations, the incidence of SAEs in the HIV-
infected subset was substantially higher than that in the overall
study population, as expected (83–94% versus 24–28% across study
and age groups throughout the study) [10]. This difference was
mostly due to the higher incidence of common childhood infec-
tious diseases and other conditions for which HIV infection
increases susceptibility (such as pneumonia, gastroenteritis,
malaria and different forms of malnutrition) [3,31–34].
The incidence of SAEs and fatal SAEs in our HIV-infected subset
of children was higher than that observed in the prior study eval-
uating RTS,S/AS01 vaccination in HIV-infected children, in which
41% of participants had at least one SAE and 5% died [13]. Partici-
pants in that study were diagnosed as HIV-infected before enroll-
ment and most received ART (to delay disease progression) and
daily cotrimoxazole (to prevent opportunistic infections) before
or soon after enrollment. By contrast, as no systematic HIV screen-
ing was done in our large phase III study and testing to confirm HIVe reported during the specified periods, overall and by age category (ITT population of
C3C
n (%, 95% CI) N n (%, 95% CI)
46 (85.2, 72.9–93.4) 48 42 (87.5, 74.8–95.3)
24 (82.8, 64.2–94.2) 32 27 (84.4, 67.2–94.7)
22 (88.0, 68.8–97.5) 16 15 (93.8, 69.8–99.8)
44 (81.5, 68.6–90.7) 48 40 (83.3, 69.8–92.5)
23 (79.3, 60.3–92.0) 32 27 (84.4, 67.2–94.7)
21 (84.0, 63.9–95.5) 16 13 (81.3, 54.4–96.0)
15 (27.8, 16.5–41.6) 48 15 (31.3, 18.7–46.3)
6 (20.7, 8.0–39.7) 32 11 (34.4, 18.6–53.2)
9 (36.0, 18.0–57.5) 16 4 (25.0, 7.3–52.4)
16 (29.6, 18.0–43.6) 48 12 (25.0, 13.6–39.6)
6 (20.7, 8.0–39.7) 32 10 (31.3, 16.1–50.0)
10 (40.0, 21.1–61.3) 16 2 (12.5, 1.6–38.3)
3 (8.6, 1.8–23.1) 28 1 (3.6, 0.1–18.3)
2 (9.1, 1.1–29.2) 20 1 (5.0, 0.1–24.9)
1 (7.7, 0.2–36.0) 8 0 (0.0, 0.0–36.9)
ses of RTS,S/AS01 plus 1 dose of comparator vaccine; C3C, group receiving 4 doses of
dose; for SAEs reported within 30 days after dose 4, N represents the number of
the event at least once; CI, confidence interval; SAE, serious adverse event.
HIV infection: ‘‘HIV infection”, ‘‘HIV infection WHO clinical stage II”, ‘‘HIV infection
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Fig. 2. Survival curves (ITT population of HIV-infected participants). ITT, intent-to-treat; R3R, group receiving 4 doses of RTS,S/AS01; R3C, group receiving 3 doses of RTS,S/
AS01 plus 1 dose of comparator vaccine; C3C, group receiving 4 doses of comparator vaccine.
Table 3
Seropositivity rates and geometric mean concentrations for anti-CS antibodies at screening and 1 month post-dose 3 in RTS,S/AS01- and comparator-vaccinated HIV-infected
participants (per protocol population for immunogenicity of HIV-infected participants).
R3C + R3R C3C
Time point N % with anti-CS  0.5 EU/mL (95% CI) GMC (95% CI), EU/mL N % with anti-CS  0.5 EU/mL (95% CI) GMC (95% CI), EU/mL
Pooled across age categories
Screening 53 15.1 (6.7–27.6) 0.3 (0.3–0.4) 21 23.8 (8.2–47.2) 0.3 (0.3–0.4)
1 month post-dose 3 53 100 (93.3–100) 188.7 (115.2–309.0) 22 18.2 (5.2–40.3) 0.5 (0.2–1.1)
5–17 months
Screening 28 14.3 (4.0–32.7) 0.3 (0.2–0.5) 16 31.3 (11.0–58.7) 0.4 (0.3–0.5)
1 month post-dose 3 29 100 (88.1–100) 264.7 (137.5–509.6) 17 23.5 (6.8–49.9) 0.5 (0.2–1.7)
6–12 weeks
Screening 25 16.0 (4.5–36.1) 0.3 (0.2–0.4) 5 0.0 (0.0–52.2) 0.3 (0.3–0.3)
1 month post-dose 3 24 100 (85.8–100) 125.3 (58.1–270.3) 5 0.0 (0.0–52.2) 0.3 (0.3–0.3)
CS, circumsporozoite; R3R, group receiving 4 doses of RTS,S/AS01; R3C, group receiving 3 doses of RTS,S/AS01 plus 1 dose of comparator vaccine; C3C, group receiving 4 doses
of comparator vaccine; N, number of participants in the per protocol population with available results, including only those confirmed as HIV-infected by 2 May 2012 (data
lock point when most children had performed their study month 20 visit); % with anti-CS  0.5 EU/mL, percentage of participants with an anti-CS antibody concentra-
tion  0.5 EU/mL; EU, enzyme-linked immunosorbent assay unit; CI, confidence interval; GMC, geometric mean concentration.
Table 4
Seropositivity rates and geometric mean concentrations for anti-CS antibodies at screening and 1 month post-dose 3 in RTS,S/AS01-vaccinated participants in the matched case-
control analysis (total vaccinated population of HIV-infected cases and their matched RTS,S/AS01-vaccinated immunogenicity controls).
R3R + R3C, HIV-infected R3R + R3C, immunogenicity controla
Time point N % with anti-CS  0.5 EU/mL (95% CI) GMC (95% CI), EU/mL N % with anti-CS  0.5 EU/mL (95% CI) GMC (95% CI), EU/mL
Screening 60 16.7 (8.3–28.5) 0.3 (0.3–0.4) 58 19.0 (9.9–31.4) 0.3 (0.3–0.4)
1 month post-dose 3 61 100 (94.1–100) 193.3 (124.1–301.0) 61 100 (94.1–100) 491.5 (406.3–594.6)
p values for the comparison of log-transformed means of anti-CS antibodies were 0.8316 at screening and 0.0001 at 1 month post-dose 3.
CS, circumsporozoite; R3R, group receiving 4 doses of RTS,S/AS01; R3C, group receiving 3 doses of RTS,S/AS01 plus 1 dose of comparator vaccine; N, number of participants in
the total vaccinated population with available results, including only those confirmed as HIV-infected or not identified as HIV-infected by 2 May 2012 (data lock point when
most children had performed their study month 20 visit); % with anti-CS  0.5 EU/mL, percentage of participants with an anti-CS antibody concentration  0.5 EU/mL; EU,
enzyme-linked immunosorbent assay unit; CI, confidence interval; GMC, geometric mean concentration.
a Immunogenicity controls were RTS,S/AS01-vaccinated with either an unknown or negative HIV status.
L. Otieno et al. / Vaccine 38 (2020) 897–906 903infection was performed based on clinical suspicion, HIV treatment
likely started at a more advanced stage of HIV in participants in our
study. In addition, the prior study had a follow-up time of
14 months after first vaccination compared to a median follow-
up time of approximately 39 months in our current analyses.Two SAEs (both febrile convulsions reported for the same child
in the 5–17 months age category) were considered related to vac-
cination. This is in line with safety data for the overall study pop-
ulation which showed an increased risk of febrile convulsion,
particularly during the first 2–3 days after RTS,S/AS01 vaccination
Fig. 3. Plain language summary presenting the findings and highlighting their clinical relevance.
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the only vaccination-related SAE reported in the prior RTS,S/AS01
study in HIV-infected children [13].
In addition to an increased risk of febrile convulsion, a higher
number of meningitis cases reported as SAE was observed in RTS,
S/AS01 compared to comparator vaccinees in the 5–17 months
age category in the overall study population of our initial large
phase III trial [7,9,10]. No such imbalance seemed apparent in
the HIV-infected subset. However, the number of meningitis cases
in this subset was low.
In the prior study in HIV-infected children, more SAEs were
observed within 30 days after RTS,S/AS01 than after rabies vacci-
nation, which the authors partially attributed to a higher number
of pneumonia cases in the RTS,S/AS01 group. However, they noted
no clustering in time-to-onset and the imbalance did not remain
until study end. In the HIV-infected subset in our current analyses,
there was no apparent imbalance in the incidence of pneumonia
within 30 days after vaccination or over the entire follow-up
period.
The numerical imbalance in overall mortality between RTS,S/
AS01 and comparator-vaccinated girls in the HIV-infected popula-
tion assessed here contributed to, but does not fully explain the
imbalance seen in the overall population of our initial large phase
III study [22].
Three doses of RTS,S/AS01 were immunogenic in our subset of
HIV-infected children, but anti-CS antibody GMCs were lower than
in the matched immunogenicity control cohort (including children
with an unknown or negative HIV status). Likewise, the prior RTS,S/
AS01 study in HIV-infected children reported lower anti-CS anti-
body GMCs 1 month post-dose 3 in HIV-infected participants com-
pared to children enrolled at the same study centers in our large
phase III efficacy study [13]. The impact of this lower immune
response on the vaccine’s protective efficacy is unknown. However,
in the prior study in HIV-infected children, RTS,S/AS01 vaccinees
experienced 37% fewer episodes of clinical malaria as well as fewersevere malaria episodes and malaria-related hospitalizations than
rabies vaccinees. While these differences were not statistically sig-
nificant (the study was not powered to measure vaccine efficacy
against these outcomes), these results indicated that, despite the
lower immunogenicity, RTS,S/AS01 might still provide some pro-
tection against malaria in HIV-infected children on ART [13]. A
reduced immunological response to vaccination in HIV-infected
children (particularly when not on ART) has been observed for sev-
eral other childhood vaccines and is likely a result of HIV infection
impairing both CD4+ T cell and memory B cell responses [28,35–
37].
Our analysis on the HIV-infected subset of the large phase III
RTS,S/AS01 trial has some limitations. Firstly, HIV testing was not
a trial procedure and was thus not done systematically on all par-
ticipants. As a result, some HIV-infected children might not have
been identified and—because HIV-testing practices and testing
rates varied among centers—different proportions may have been
missed in the different centers. The real impact of HIV infection
on the anti-CS immune response may have been overestimated if
mostly more advanced stages of HIV were clinically diagnosed
and included in the HIV-infected subset. Alternatively, the impact
may have been underestimated if unknown HIV-infected children
were included as immunogenicity controls. Secondly, HIV-
infected individuals were not randomized to the RTS,S/AS01 or
comparator vaccine groups. However, approximately equal pro-
portions of HIV-infected children were identified in all groups
and most baseline characteristics were comparable between the
groups in the HIV-infected subset. Thirdly, the lack of information
on ART use and HIV disease progression (CD4 counts and viral
load), both of which may influence safety and immunogenicity
results, are limitations in fully understanding the generalizability
of the study findings. This was however assessed in detail in the
prior study in HIV-infected children [13].
Our results contribute to the overall risk-benefit assessment of
the RTS,S/AS01 vaccine. In contrast to the prior study, which only
L. Otieno et al. / Vaccine 38 (2020) 897–906 905enrolled HIV-infected children [13], our results allow a direct com-
parison of the safety and immunogenicity of RTS,S/AS01 in HIV-
infected children with those in the overall study population
(HIV-infected and uninfected) in the same settings. The prior study
in HIV-infected children evaluated a 3-dose vaccination course (0,
1, 2 months) with a follow-up of 14 months [13] while the current
analyses also included the safety of a fourth dose given 18 months
after dose 3 and had a follow-up of more than 3 years after first
vaccination. The prior study was conducted at two sites in Kenya,
while our current analyses also provided data on children in other
sub-Saharan countries. HIV testing was not a study procedure in
our large phase III trial and thus was done according to daily prac-
tice in the different study centers. This might therefore more clo-
sely reflect a real-life situation where children may be vaccinated
without knowledge of their HIV status and/or without having
started ART.
5. Conclusions
Our analyses on the subset of children identified as HIV-
infected during the large phase III RTS,S/AS01 trial in sub-
Saharan Africa indicate that the incidence of SAEs and deaths in
RTS,S/AS01-vaccinated HIV-infected children is similar to that in
MenC-CRM- or rabies-vaccinated HIV-infected children. RTS,S/
AS01 is immunogenic in this population, although at a lower level
than in the general population of children. This, together with
results from the prior RTS,S/AS01 study in HIV-infected children,
suggests that RTS,S/AS01 would be expected to provide some pro-
tection against malaria in HIV-infected children. Based on these
data, we see no reason why the RTS,S/AS01 vaccine would be con-
traindicated in infants and children with stage I/II HIV disease,
which is in line with recommendations for other non-replicating,
recombinant vaccines [38].
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